When doctors told Australian Greg Jefferys he had hepatitis C and the disease was destroying his liver, the devastating diagnosis was compounded by the cost of a cure.
Unable to afford Sovaldi, hailed as a miracle drug, the 61-year-old flew to India, one of a growing army of patients seeking out low-cost, life-saving medicines on the subcontinent.
Their illnesses vary — hepatitis C, cancer and HIV are among the most common — but they are almost always desperate, seeing in India their only hope to save their life or that of a loved one.
Photo: AFP
They contact underground “buyers clubs,” make the trip to India to buy from a legitimate distributor or seek out shady online pharmacies promising mail-order cures.
“The doctors told me ‘you’ve got Hepatitis C, you’ve probably got liver cancer,’” said Jefferys, a PhD student.
“The chatter was around the new generic versions of Sovaldi being released in India. I hopped on a plane to Chennai and in about two days I had an appointment with a specialist,” he said.
India earned a nickname as “the pharmacy to the developing world” for its tough stance on patents.
Successive governments have taken a view that patents should be granted only for major innovations, not updates to existing compounds — allowing domestic manufacturers to make generic versions of drugs at vastly lower cost.
Sovaldi, chemically known as sofosbuvir, is made by US pharmaceutical giant Gilead and costs US$84,000 for a 12-week cycle of treatment in the US.
Rejected for a patent in India, generic drug makers, some licensed by Gilead, produce versions such as Mylan’s MyHep, that cost less than US$900 a cycle.
“This is something I observe more and more,” said Leena Menghaney, who runs Medecins Sans Frontieres’ Access Campaign in India, which works to broaden access to drugs.
“All kinds of people and patients across the world are starting to access medicines from India. They travel themselves, or they contact a friend,” she said.
More than 130 million people live with chronic hepatitis C worldwide, according to the WHO, and 500,000 die each year from related liver diseases.
Since writing a blog, Jefferys receives 150 e-mails a day from people in the US, Britain and elsewhere asking for help.
When Loon Gangte, a Delhi-based HIV activist, was diagnosed with the virus in 1997, the price of treatment was far beyond his reach.
However, the advent of generic Indian anti-retrovirals saved his life — and made the country a global center for cheap, lifesaving HIV drugs.
Gangte is open about carrying medicines overseas for others and says in a decade he has been stopped just once, at Thai customs, and fined.
Most countries allow patients to import small amounts of medicines only for personal use.
Campaigning by activists like Gangte for better access to HIV treatments helped give rise to so-called buyers clubs, made famous by the 2013 Hollywood film.
“When I saw Dallas Buyers Club, I laughed,” said a woman who asked to be called Meera,who helps one Delhi club by ferrying drugs illegally in her suitcase whenever she travels. “I hate the term ‘drug tourism.’ This is about saving lives.”
Dinesh (not his real name), a long-time HIV campaigner, began working full-time for the same buyers club in August last year, helping people obtain medicines for a nominal fee.
He is not sure how people find him — he has no online presence — but gets requests from as far afield as Austria and Indonesia.
“My family were a bit reluctant, there is always a grey area in this, but I fear only the one above. I feel completely that this is right,” he said.
Pharmaceutical firms say India’s disregard for patents will stifle innovation or make drugs commercially unfeasible — Gilead paid US$11 billion to buy the developer of Sovaldi in 2012.
However, after losing several high-profile patent battles, it appears drugmakers can do little to combat the Indian government’s will or that of overseas patients determined to import drugs.
Gilead spokesman Nick Francis said the company was “aware such activity may occur.”
Perhaps the riskiest route is online pharmacies — a search on e-marketplace IndiaMart turns up dozens claiming to sell generics — with no guarantee against counterfeits.
However, legal channels are springing up, including Delhi-based Ikris Pharma Network, set up in August 2014, which does not sell drugs, but connects patients to genuine distributors.
Founder Praveen Sikri receives 70 calls a day from people struggling to access drugs, including generic Veenat, for cancer.
“Either the drug is not available or it is very expensive,” Sikri said. “We help the patient to get the product in a legalized manner.”
One recent e-mail is from a young man in San Francisco whose grandad desperately needs medicine for a stomach tumor.
In India, one way or another, he will probably be able to find it.
“There are many, many people doing this,” Sikri said.
Elon Musk’s lieutenants have reached out to chip industry suppliers, including Applied Materials Inc, Tokyo Electron Ltd and Lam Research Corp, for his envisioned Terafab, early steps in an audacious and likely arduous attempt to break into the production of cutting-edge chips. Staff working for the joint venture between Tesla Inc and Space Exploration Technologies Corp (SpaceX) have sought price quotes and delivery times for an array of chipmaking gear, people familiar with the matter said. In past weeks, they’ve contacted makers of photomasks, substrates, etchers, depositors, cleaning devices, testers and other tools, according to the people, who asked not to
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
Japan approved ￥631.5 billion (US$3.97 billion) in additional subsidies to hasten Rapidus Corp’s entry into the high-stakes artificial intelligence (AI) chipmaking arena, ramping up support for a project widely regarded as a long shot. The capital is intended to bankroll Rapidus’ work for information technology firm Fujitsu Ltd, one of the initial customers that Tokyo hopes would get the signature endeavor off the ground. The new money raises the fees and investments that the government is injecting into the start-up to ￥2.6 trillion by the end of the current fiscal year to March next year, the Japanese Ministry of Economy, Trade and
The founder of Chinese property giant Evergrande Group (恆大集團) has pleaded guilty to charges of fraud and bribery, a court said yesterday, the latest blow for what was once the country’s leading developer. Evergrande’s rise was propelled by decades of rapid urbanization and rising living standards, but in 2020, its access to credit dramatically narrowed when the government introduced curbs on excessive borrowing and speculation. The company defaulted in 2021 after struggling to repay creditors. Founder Xu Jiayin (許家印), 67, known as Hui Ka Yan in Cantonese, was reportedly held by police in 2023, with Evergrande saying he had been subjected to
RSS